# An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

> **NCT06985316** · NA · NOT_YET_RECRUITING · sponsor: **Liu Huang** · enrollment: 34 (estimated)

## Conditions studied

- CRC, Colorectal Cancer

## Interventions

- **DRUG:** Tunlametinib combined with Fruquintinib

## Key facts

- **NCT ID:** NCT06985316
- **Lead sponsor:** Liu Huang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-19
- **Primary completion:** 2028-04-27
- **Final completion:** 2028-04-27
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06985316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06985316, "An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06985316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*